Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2015

View Archived Issues

Activation of engram cells by positive memories may suppress depression-related behaviors

Apceth and University of Cologne to develop cellular immunotherapies for cancer

Eligo Bioscience's development of antibiotics supported by new investment

Toulouse University Cancer Institute and Pierre Fabre sign framework agreement in oncology

Cleveland BioLabs reports data from phase I study of CBLB-612

Allegro Ophthalmics reports topline data from phase II study of Luminate

C3 Jian completes second phase II study of C16G2

Preliminary data presented on safety, PK and PD of PF-0538062 for hemophilia

FDA approves Iressa for metastatic NSCLC with certain EGFR mutations

Clozapine is a potent antiplatelet agent

Ferring to collaborate with Intralytix on bacteriophage therapy for IBD

Roche discloses V1A receptor antagonists

Cav2.2 blockers developed at Gruenenthal

Sunshine Lake Pharma reports 5-HT6 antagonists

Bayer Schering Pharma discloses EP4 antagonists

Bayer Schering Pharma presents alpha2C-adrenoceptor antagonists

RaQualia begins first-in-human study of 5-HT2B antagonist RQ-00310941

Anacor discloses positive results from phase III trials of crisaborole in atopic dermatitis

Phase III ENSPIRIT trial of custirsen sodium continues following final interim futility analysis

Blueprint Medicines receives FDA clearance to start phase I trials of BLU-554 and BLU-285

New phase I study investigates cabozantinib in combination therapy for genitourinary tumors

Results of in vivo neuroblastoma study of anisina plus vincristine

ACT-246475 shows a wider therapeutic window than ticagrelor

Researchers develop an improved p21 reporter mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...